RBCL (RBC Life Sciences) YoY EBITDA Growth: -4.08% (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RBC Life Sciences YoY EBITDA Growth?

RBC Life Sciences RBCL YoY EBITDA Growth is -4.08% as of Jun. 2017.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. RBC Life Sciences's YoY EBITDA Growth for the quarter that ended in Jun. 2017 was -4.08%.

RBC Life Sciences's EBITDA per Share for the three months ended in Jun. 2017 was $-0.05.

RBC Life Sciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for RBC Life Sciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RBC Life Sciences YoY EBITDA Growth Chart

RBC Life Sciences Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.45 -129.63 -25.00 -585.00 16.79

RBC Life Sciences Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.99 -42.49 27.85 113.44 -4.08

RBC Life Sciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

RBC Life Sciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2016 is calculated as:

YoY EBITDA Growth (A: Dec. 2016 )
=(EBITDA per Share (A: Dec. 2016 )-EBITDA per Share (A: Dec. 2015 ))/ | EBITDA per Share (A: Dec. 2015 ) |
=(-0.114--0.137)/ | -0.137 |
=16.79 %

RBC Life Sciences's YoY EBITDA Growth for the quarter that ended in Jun. 2017 is calculated as:

YoY EBITDA Growth (Q: Jun. 2017 )
=(EBITDA per Share (Q: Jun. 2017 )-EBITDA per Share (Q: Jun. 2016 )) / | EBITDA per Share (Q: Jun. 2016 )) |
=(-0.051--0.049)/ | -0.049 |
=-4.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -4.08% mean?
RBC Life Sciences (RBCL) has a YoY EBITDA Growth of -4.08% as of Jun. 2017. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for RBC Life Sciences and its competitors.
Is RBC Life Sciences' YoY EBITDA Growth too high?
RBC Life Sciences' current YoY EBITDA Growth is -4.08%.
How does RBC Life Sciences' YoY EBITDA Growth compare to SKVI and TISUQ?
RBC Life Sciences' YoY EBITDA Growth of -4.08% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Consumer Packaged Goods company?
A good YoY EBITDA Growth depends on the Consumer Packaged Goods industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for RBC Life Sciences and its competitors. RBC Life Sciences's current YoY EBITDA Growth is -4.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Life Sciences stock overvalued right now?
RBC Life Sciences (RBCL) has a current YoY EBITDA Growth of -4.08%. The current YoY EBITDA Growth is -4.08%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For RBC Life Sciences (RBCL), the current YoY EBITDA Growth is -4.08% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RBC Life Sciences Business Description

Address 2301 Crown Court, Irving, TX, USA, 75038
RBC Life Sciences Inc, through its subsidiaries, is engaged in marketing and distribution of nutritional supplements and personal care products. Its products include herbal formulas, vitamins, minerals, antioxidants, and skin, hair and body care products. It also markets its Nutritional Products in certain international markets through license arrangements. In addition to its Nutritional Products, the company also markets a line of wound care products under the MPM Medical brand name through a U.S. subsidiary.